

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
May 25, 2016

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

LaToya Bonner, PharmD, NCPS

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Daniel Budnitz, MD, MPH

Medical Officer, Division of Healthcare Quality
Promotion
Director, Medication Safety Program
Centers for Disease Control and Prevention
Atlanta, Georgia

Diana Hallare, MPH

(Consumer Representative)
Visalia, California

Robert J. Smith, MD

(Chairperson)
Professor of Medicine (Endocrinology)
The Warren Alpert School of Medicine
Professor of Health Services, Policy and Practice
Brown University
Providence, Rhode Island

Peter W. F. Wilson, MD

Director
Epidemiology and Genomic Medicine
Atlanta Veterans Administration Medical Center
Professor of Medicine and Public Health
Emory University
Emory Clinical Cardiovascular Research Institute
Atlanta, Georgia

Brendan M. Everett, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Director, General Cardiology Inpatient Service
Brigham and Women's Hospital
Boston, Massachusetts

James D. Neaton, PhD

Professor of Biostatistics
Division of Biostatistics
School of Public Health
University of Minnesota
Minneapolis, Minnesota

Charles A. Stanley, MD

Professor of Pediatrics
University of Pennsylvania
Perelman School of Medicine
Division of Endocrinology
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Susan Z. Yanovski, MD

Co-Director, Office of Obesity Research
Senior Scientific Advisor for Clinical Obesity
Research
National Institute of Diabetes and Digestive and
Kidney Diseases
National Institutes of Health (NIH)
Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
May 25, 2016

MEETING ROSTER (cont.)

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Reshma Kewalramani, MD

(Industry Representative)

Vice President, US Medical Organization
Amgen
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

Barbara Berney

(Patient Representative)

Rockford, Illinois

Kenneth Burman, MD

Director, Section of Endocrinology
MedStar Washington Hospital Center
Director, Integrated Endocrine Training Program
MedStar Georgetown University Hospital
Washington, District of Columbia

Timothy S. Lesar, PharmD

Patient Care Service Director
Director of Clinical Pharmacy Services
Albany Medical Center
Albany, New York

Steven B. Meisel, PharmD

System Director of Patient Safety
Fairview Health Services
Minneapolis, Minnesota

Martha C. Nason, PhD

Mathematical Statistician
Division of Clinical Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, Maryland

Michael D. Reed, PharmD, FCCP, FCP

Director
Rainbow Clinical Research Center
Rainbow Babies and Children's Hospital
University Hospitals Case Medical Center
Cleveland, Ohio

Ellen W. Seely, MD

Professor of Medicine
Harvard Medical School
Brigham and Women's Hospital
Boston, Massachusetts

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
May 25, 2016

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Mary Parks, MD

Deputy Director
Office of Drug Evaluation II (ODE-II)
Office of New Drugs (OND), CDER, FDA

Jean-Marc Guettier, MDCM

Director
Division of Metabolism and Endocrinology Products
(DMEP)
ODE-II, OND, CDER, FDA

Lubna Merchant, MS, PharmD

Deputy Director
Division of Medication Error Prevention and
Analysis (DMEPA)
Office of Medication Error Prevention and Risk
Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
CDER, FDA

William Chong, MD

Clinical Team Leader
DMEP, ODE-II, OND, CDER, FDA

Suchitra Balakrishnan, MD, PhD

Clinical Reviewer
DMEP, ODE-II, OND, CDER, FDA